Portfolio concentration
As of March 31, 2026 · N-PORT
Holdings
62
Top-10 weight
46.69%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
31
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
582.2
Holdings
As of March 31, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | FIRST AM-TR OB-X | TMPXX | 3,035,293 | $3.04M | 7.72% |
| 2 | GILEAD SCIENCES INC | — | 20,260 | $2.82M | 7.18% |
| 3 | AstraZeneca PLC ORD USD0.25 | AZN LN | 11,232 | $2.22M | 5.63% |
| 4 | VERTEX PHARMACEUTICALS INC | — | 4,931 | $2.20M | 5.60% |
| 5 | IONIS PHARMACEUTICALS INC | — | 19,587 | $1.47M | 3.74% |
| 6 | INSMED INC | — | 8,583 | $1.40M | 3.57% |
| 7 | INCYTE CORP | — | 14,245 | $1.34M | 3.41% |
| 8 | ROIVANT SCIENCES | — | 47,667 | $1.32M | 3.36% |
| 9 | ARGENX SE SPONSORED ADR | — | 1,794 | $1.31M | 3.33% |
| 10 | NEUROCRINE BIOSCIENCES INC | — | 9,607 | $1.27M | 3.22% |
| 11 | AXSOME THERAPEUTICS INC | — | 6,438 | $1.09M | 2.77% |
| 12 | Ascendis Pharma A/S | — | 4,526 | $1.04M | 2.63% |
| 13 | APOGEE THERAPEUTICS INC | — | 11,369 | $956.93K | 2.43% |
| 14 | PROTAGONIST THERAPEUTICS INC | — | 9,040 | $952.82K | 2.42% |
| 15 | AMGEN INC | — | 2,329 | $819.46K | 2.08% |
| 16 | RHYTHM PHARMACEUTICALS INC | — | 9,297 | $808.56K | 2.06% |
| 17 | ABBVIE INC | — | 3,544 | $770.78K | 1.96% |
| 18 | BIOGEN INC | — | 3,835 | $703.07K | 1.79% |
| 19 | SANOFI SPON ADR | SNY US | 14,382 | $692.92K | 1.76% |
| 20 | JAZZ PHARMACEUTI | — | 3,561 | $673.21K | 1.71% |
| 21 | CATALYST PHARMACEUTICALS INC | — | 23,286 | $576.56K | 1.47% |
| 22 | ORUKA THERAPEUTICS INC | — | 11,506 | $564.37K | 1.44% |
| 23 | BIONTECH SE ADR | — | 5,616 | $499.15K | 1.27% |
| 24 | KRYSTAL BIOTECH INC | — | 1,918 | $495.46K | 1.26% |
| 25 | EDGEWISE THERAPEUTICS INC | — | 15,615 | $491.87K | 1.25% |
| 26 | NUVALENT INC-A | — | 4,657 | $477.11K | 1.21% |
| 27 | AGIOS PHARMACEUTICALS INC | — | 13,971 | $472.64K | 1.20% |
| 28 | NEWAMSTERDAM PHARMA CO NV COMMON STOCK | NAMS US | 14,656 | $469.14K | 1.19% |
| 29 | MEIRAGTX HOLDINGS PLC COMMON STOCK USD.00001 | MGTX US | 53,694 | $464.99K | 1.18% |
| 30 | ALNYLAM PHARMACEUTICALS INC | — | 1,370 | $453.29K | 1.15% |
| 31 | KYMERA THERAPEUTICS INC | — | 5,342 | $444.94K | 1.13% |
| 32 | PERSONALIS INC | — | 64,032 | $407.88K | 1.04% |
| 33 | CELLDEX THERAPEUTICS INC | — | 12,614 | $400.12K | 1.02% |
| 34 | NURIX THERAPEUTICS INC | — | 25,571 | $396.35K | 1.01% |
| 35 | Abivax SA SPONSORED ADS | ABVX US | 3,424 | $381.26K | 0.97% |
| 36 | CYTOKINETICS INC | — | 5,616 | $370.15K | 0.94% |
| 37 | SPYRE THERAPEUTICS INC | — | 6,634 | $334.62K | 0.85% |
| 38 | HALOZYME THERAPEUTICS INC | — | 4,794 | $309.84K | 0.79% |
| 39 | CULLINAN THERAPE | — | 20,135 | $286.12K | 0.73% |
| 40 | TREVI THERAPEUTICS INC | — | 23,970 | $285.96K | 0.73% |
| 41 | NATERA INC | — | 1,370 | $273.99K | 0.70% |
| 42 | XERIS BIOPHARMA HOLDINGS INC | — | 45,886 | $266.14K | 0.68% |
| 43 | DISC MEDICINE INC | — | 3,972 | $253.97K | 0.65% |
| 44 | DESIGN THERAPEUTICS INC | — | 21,231 | $225.90K | 0.57% |
| 45 | VERACYTE INC | — | 6,838 | $220.25K | 0.56% |
| 46 | REZOLUTE INC | — | 71,227 | $217.24K | 0.55% |
| 47 | TECTONIC THERAPEUTIC INC | — | 6,849 | $211.70K | 0.54% |
| 48 | Wave Life Sciences Ltd. COM NPV | WVE US | 29,175 | $211.52K | 0.54% |
| 49 | MONTE ROSA THERAPEUTICS INC | — | 12,566 | $206.71K | 0.53% |
| 50 | RAPPORT THERAPEUTICS INC | — | 6,438 | $201.45K | 0.51% |
1 / 2
Next ›
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.